As the division of labor within the pharmaceutical industry chain increasingly exhibits characteristics of specialization, refinement, and customization, the pharmaceutical contract outsourcing service industry represented by Contract Development and Manufacturing Organization (CDMO) has emerged as a necessity and rapidly risen to become an indispensable part of the global pharmaceutical industry. The booming innovation drug industry has provided broad development space for the CDMO industry, while CDMO companies, relying on their large-scale production capabilities and high-tech value-added R&D and production processes, have become key partners assisting pharmaceutical companies in bridging the entire chain from drug concept to market launch, from process R&D to large-scale production. In recent years, Chinese CDMO companies have actively explored international markets with a global development perspective. Through a series of strategic measures such as establishing overseas R&D centers and building production bases that meet international standards, they have deeply participated in the competition and cooperation of the global pharmaceutical industry, injecting new vitality into the development of the global pharmaceutical industry.
Against this backdrop, Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') has authored the '2025 China Pharmaceutical CDMO Industry Development Insights Blue Book' (hereinafter referred to as 'Blue Book'). The Blue Book delves into the macro environment and industrial development patterns of the global and Chinese CDMO industries, systematically sorts out the strategic development paths and international expansion of Chinese CDMO enterprises, objectively analyzes industry barriers and current development challenges, and prospectively tracks the future development potential of the Chinese CDMO industry.
The English version of the report ('2025 China Pharmaceutical CDMO Industry Insight Blue Book') will be released on the Frost & Sullivan global website and is being synchronized with top global communications agencies (such as the Associated Press), mainstream financial media (such as Yahoo Finance), top North American financial media and websites (Business Insider, Dow Jones MarketWatch, Benzinga, Wall Street Insider, etc.), as well as top regional media around the world. Leveraging Frost & Sullivan's professional industry analysis, global distribution network, and industrial resource network, it effectively supports the internationalization strategy of Chinese pharmaceutical CDMO enterprises.
